Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Breast Neoplasms 18Triple Negative Breast Neoplasms 16Carcinoma, Transitional Cell 4Neoplasm Metastasis 3Carcinoma, Non-Small-Cell Lung 3Salivary Gland Neoplasms 2Lung Neoplasms 2Colorectal Neoplasms 2Brain Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Locally Advanced Non-resectable Breast Cancer 1Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Oropharyngeal Neoplasms 1Neoplasm, Residual 1Mouth Neoplasms 1Metastatic Urothelial Cancer 1Meningeal Carcinomatosis 1Lung Diseases 1Localized Muscle Invasive Bladder Urothelial Carcinoma 1Liver Failure 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1

Interventions

Paclitaxel 4pembrolizumab 3Cisplatin 3Doxorubicin 2Carboplatin 2Brachytherapy 2Biopsy 2trastuzumab deruxtecan 1sacituzumab govitecan 1relugolix 1dostarlimab 1dehydroftorafur 1belzutifan 1Watchful Waiting 1Vaginal Smears 1VMBP protocol 1Ultrasound, High-Intensity Focused, Transrectal 1Transurethral Resection of Prostate 1Taxes 1Sutures 1Standard of Care 1Radiotherapy, Intensity-Modulated 1Pregnancy Tests 1Practice Guidelines as Topic 1Platinum 1Papanicolaou Test 1Oxaliplatin 1Mitozytrex 1Mitomycin 1Magnetic Resonance Spectroscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Uterine Neoplasms × sacituzumab govitecan × Clear all
NCT06040970 2025-12-02

Sacituzumab Govitecan in Combination With Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer

Icahn School of Medicine at Mount Sinai

Phase 1/2 Recruiting
54 enrolled
Gynecologic

Ovarian Neoplasms, Uterine Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡